Syracuse

Idarucizumab (Praxbind ® ) for dabigatran reversal in patients undergoing heart transplantation: a cohort of ten patients

Archive ouverte

Kalmanovich, Eran | Battistella, Pascal | Rouviere, Philippe | Albat, Bernard | Frapier, Jean-Marc | Demaria, Roland | Huet, Fabien | Agullo, Audrey | Mourad, Marc | Colson, Pascal | Leclercq, Florence | Gaudard, Philippe | Roubille, François

Edité par CCSD ; Future Science Ltd -

International audience. Background: Novel oral anticoagulants are used in atrial fibrillation. Idarucizumab has been approved for reversal of dabigatran in situations of life-threatening hemorrhage or emergency surgery.Objectives: We report a single center experience of ten patients on dabigatran therapy who were given idarucizumab prior to heart transplantation. Methods & results: The mean plasma concentration of dabigatran prior to reversal was 139 ± 89 ng/ml. Hemoglobin, hematocrit and platelet levels were decreased after surgery. Surgical procedures were successfully performed with no increased risk, especially regarding bleeding complications. All patients were alive after 90 days.Conclusion: Dabigatran reversal with idarucizumab in contexts of emergency surgery/urgent procedures is an attractive and safe option to be taken into consideration for patients with end stage heart disease awaiting transplantation and indication of anticoagulant therapy.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion